Gyre Therapeutics, Inc. GYRE Business Segments
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| Revenue by Business | ||||||
| Gyre Pharmaceuticals | $117.05M+0.4% | $116.59M+8.7% | $107.27M+5.0% | $102.19M+1.5% | $100.64M-4.8% | |
| Revenue (Gross) by Product | ||||||
| Contiva | $5.52M0.0% | $5.52M— | —— | —— | —— | |
| Square Meter Area For Laboratory Center Under Lease by Geography | ||||||
| Nanjing | 2800.0% | 280— | —— | —— | —— | |
| Shanghai | 8960.0% | 896— | —— | —— | —— | |
| Zhengzhou | 7200.0% | 720— | —— | —— | —— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Gyre Therapeutics, Inc. break its business down?
- Gyre Therapeutics, Inc. (GYRE) reports revenue by business across 3 parts — All Other Segments, Gyre Pharmaceuticals and Gyre. Each is extracted from the segment footnotes and tracked over time.
- Where does Gyre Therapeutics, Inc.'s segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Gyre Therapeutics, Inc.'s SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
